Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
Mi Sung Park, Beom Kyung Kim, Kyung Sik Kim, Ja Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Oidov Baartarkhuu, Kwang Hyub Han, Chae Yoon Chon, Sang Hoon Ahn
Clin Mol Hepatol. 2013;19(1):29-35.   Published online 2013 Mar 25     DOI: https://doi.org/10.3350/cmh.2013.19.1.29
Citations to this article as recorded by Crossref logo
ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis
Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim
Clinical Gastroenterology and Hepatology.2023; 21(9): 2278.     CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Korean Medical Science.2021;[Epub]     CrossRef
Entecavir-based combination therapies for chronic hepatitis B
Aoran Luo, Xiaoyan Jiang, Hong Ren
Medicine.2018; 97(51): e13596.     CrossRef
Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China
Keng Lai, Chi Zhang, Weixia Ke, Yanhui Gao, Shudong Zhou, Li Liu, Yi Yang
Clinical Drug Investigation.2017; 37(3): 233.     CrossRef
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
Song Yang, Huichun Xing, Qi Wang, Xiaomei Wang, Shunai Liu, Jun Cheng
Annals of Clinical Microbiology and Antimicrobials.2016;[Epub]     CrossRef
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon
Clinical and Molecular Hepatology.2016; 22(2): 241.     CrossRef
Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B
YANG WANG, SHUANG LIU, YU CHEN, SUJUN ZHENG, LI ZHOU, FENGMIN LU, ZHONGPING DUAN
Experimental and Therapeutic Medicine.2016; 11(6): 2293.     CrossRef
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
Sung Soo Ahn, Young Eun Chon, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
Clinical and Molecular Hepatology.2014; 20(3): 261.     CrossRef
Oral antiviral agents for treatment of chronic hepatitis B
Soon Young Ko, Won Hyeok Choe
Journal of the Korean Medical Association.2014; 57(1): 60.     CrossRef
Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment
A. K. Singh, M. K. Sharma, S. S. Hissar, E. Gupta, S. K. Sarin
Journal of Viral Hepatitis.2014; 21(6): 439.     CrossRef
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
Hyung Joon Yim, Seong Gyu Hwang
Clinical and Molecular Hepatology.2013; 19(3): 195.     CrossRef